Information  X 
Enter a valid email address

Company Name matching 'Sanofi'

Date
Time Source
Company
Announcement
18 Jun 2021 2:45 pm GNW   Sanofi European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
11 Jun 2021 8:00 am GNW   Sanofi New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia 
07 Jun 2021 5:00 pm GNW   Sanofi Sanofi launches its new global employee share ownership plan
04 Jun 2021 6:00 am GNW   Sanofi Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
03 Jun 2021 1:00 pm GNW   Sanofi Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
01 Jun 2021 6:00 am GNW   Sanofi Sanofi provides update on venglustat clinical program
27 May 2021 6:30 am GNW   Sanofi Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
19 May 2021 10:45 pm GNW   Sanofi Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
  10:00 pm GNW   Sanofi Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
17 May 2021 3:00 pm GNW   Sanofi Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
  6:30 am GNW   Sanofi Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
06 May 2021 6:00 am GNW   Sanofi Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30 Apr 2021 4:56 pm GNW   Sanofi Annual General Meeting of April 30, 2021
28 Apr 2021 6:30 am GNW   Sanofi Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26 Apr 2021 7:00 am GNW   Sanofi Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23 Apr 2021 3:05 pm GNW   Sanofi New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19 Apr 2021 6:00 am GNW   Sanofi European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12 Apr 2021 6:00 am GNW   Sanofi Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09 Apr 2021 6:45 pm GNW   Sanofi Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
  5:01 am GNW   Sanofi Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07 Apr 2021 8:03 am GNW   Sanofi Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31 Mar 2021 10:15 pm GNW   Sanofi FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
  3:05 pm GNW   Sanofi Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19 Mar 2021 6:30 am GNW   Sanofi Availability of the Q1 2021 Memorandum for modelling purposes
15 Mar 2021 6:00 am GNW   Sanofi Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival 
12 Mar 2021 6:00 am GNW   Sanofi Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04 Mar 2021 5:18 pm GNW   Sanofi Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
  6:00 am GNW   Sanofi FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03 Mar 2021 5:00 pm GNW   Sanofi Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
22 Feb 2021 6:00 pm GNW   Sanofi FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
  10:40 am GNW   Sanofi Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
12 Feb 2021 6:00 am GNW   Sanofi The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
09 Feb 2021 10:15 pm GNW   Sanofi FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
05 Feb 2021 6:30 am GNW   Sanofi Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
  6:30 am GNW   Sanofi Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
12 Jan 2021 1:30 pm GNW   Sanofi SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
11 Jan 2021 7:30 am GNW   Sanofi Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
17 Dec 2020 9:30 pm GNW   Sanofi Availability of the Q4 2020 Memorandum for modelling purposes
15 Dec 2020 6:00 am GNW   Sanofi Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
11 Dec 2020 1:30 pm GNW   Sanofi CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes
  6:00 am GNW   Sanofi Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
09 Dec 2020 6:00 am GNW   Sanofi Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
30 Nov 2020 6:00 am GNW   Sanofi Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
23 Nov 2020 9:00 am GNW   Sanofi European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18 Nov 2020 6:12 pm GNW   Sanofi European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
  6:15 am GNW   Sanofi Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
  6:00 am GNW   Sanofi FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14 Nov 2020 12:00 am GNW   Sanofi FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02 Nov 2020 6:15 am GNW   Sanofi Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29 Oct 2020 1:50 pm GNW   Sanofi European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
  6:30 am GNW   Sanofi Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
  6:00 am GNW   Sanofi Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28 Oct 2020 6:00 am GNW   Sanofi Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26 Oct 2020 12:00 pm GNW   Sanofi Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16 Oct 2020 1:00 pm GNW   Sanofi CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15 Oct 2020 1:00 pm GNW   Sanofi Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13 Oct 2020 6:00 am GNW   Sanofi Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02 Oct 2020 6:00 am GNW   Sanofi EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28 Sep 2020 2:30 pm GNW   Sanofi Sanofi completes Principia Biopharma Inc. acquisition
25 Sep 2020 6:30 am GNW   Sanofi Availability of the Q3 2020 Memorandum for modelling purposes


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t